Akari Therapeutics annual free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
Akari Therapeutics Free Cash Flow (FCF) History (AKTX)
Akari Therapeutics reported −$12.9M in free cash flow for fiscal 2019, an increase of $9.9M from the previous fiscal year.
View full Akari Therapeutics company overviewAkari Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2019 | 2019-12-31 | −$12.9M | $9.9M | — | — |
| 2018 | 2018-12-31 | −$22.8M | $8.9M | — | — |
| 2017 | 2017-12-31 | −$31.6M | −$7.0M | — | — |
| 2016 | 2016-12-31 | −$24.7M | −$19.7M | — | — |
| 2015 | 2015-12-31 | −$5.0M | −$3.5M | — | — |
| 2014 | 2014-12-31 | −$1.5M | $4.0M | — | — |
| 2013 | 2013-12-31 | −$5.5M | −$3.3M | — | — |
| 2012 | 2012-12-31 | −$2.1M | −$1.1M | — | — |
| 2011 | 2011-12-31 | −$1.0M | −$642,000 | — | — |
| 2010 | 2010-12-31 | −$366,000 | — | — | — |
Akari Therapeutics quarterly free cash flow
Q1.15
Q2.15
Q1.16
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q1 2016 | 2016-03-31 | −$7.5M | — | — | — |
| Q2 2015 | 2015-06-30 | −$1.5M | — | — | — |
| Q1 2015 | 2015-03-31 | −$2.0M | — | — | — |
Akari Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$1.5M to −$12.9M, a net decrease of $11.4M. Akari Therapeutics's latest reported quarter, Q1 2016, generated −$7.5M in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Akari Therapeutics filings at SEC.gov ↗